SCNA amiRNA gene therapy (Sanofi)

N/A

Report date: 2025/12/12 17:32:05

Base Information

Drug NameSCNA amiRNA gene therapy (Sanofi)
Drug Alias NameSCNA artificial-miRNA therapy (Sanofi)AAV-amiRNA-SCNASCNA gene-targeted AAV-artificial microRNA (Sanofi)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionSynuclein alpha inhibitorsNeuroprotectants
TargetsSynuclein alpha
Therapy Area/IndicationsParkinson DiseaseLewy Body DiseaseMultiple System Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi
Inactive CompaniesN/A
Active IndicationsParkinson DiseaseLewy Body DiseaseMultiple System Atrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A